Crispr Therapeutics AG (CRSP) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Crispr Therapeutics AG (US:CRSP), currently being evaluated. In 2025, Crispr Therapeutics AG generated $3.51 Million in revenue and -$345.93 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Crispr Therapeutics AG is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $3.51 Million
- Free Cash Flow (2025): -$345.93 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.